Phase I Study of In Situ Autologous Vaccination Against Prostate Cancer With Intratumoral and Systemic Hiltonol® (Poly-ICLC) Prior To Radical Prostatectomy
Latest Information Update: 14 Jun 2024
At a glance
- Drugs Poly ICLC (Primary) ; Poly ICLC (Primary)
- Indications Adenocarcinoma; Prostate cancer
- Focus Adverse reactions
- 08 Sep 2022 Status changed from recruiting to completed.
- 23 Apr 2020 Planned End Date changed from 1 May 2020 to 1 May 2022.
- 23 Apr 2020 Planned primary completion date changed from 1 May 2020 to 1 May 2022.